Matinas BioPharma
MTNB
35 hedge funds and large institutions have $8.24M invested in Matinas BioPharma in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 10 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
25% more capital invested
Capital invested by funds: $6.6M → $8.24M (+$1.64M)
13% more funds holding
Funds holding: 31 → 35 (+4)
0.09% more ownership
Funds ownership: 0.15% → 0.25% (+0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$4.43M |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
+$960K |
| 3 |
AGM
Alpine Global Management
New York
|
+$324K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$179K |
| 5 |
BlackRock
New York
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$261K |
| 2 |
ECM
Element Capital Management
New York
|
-$231K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
-$187K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$178K |
| 5 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
-$150K |
MTNB Hedge Fund Activity: Q4 2018 in Review
35 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2018, worth a combined $8.24M — up 25% from $6.6M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new MTNB positions and 10 closed out — a net gain of 4 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $4.43M. The largest seller was Goldman Sachs, exiting entirely with an estimated $261K sold.
- 35 institutional investors held Matinas BioPharma (MTNB) as of Q4 2018, up from 31 in Q3 2018.
- Funds reported $8.24M of Matinas BioPharma stock for Q4 2018, up 25% quarter-over-quarter.
- 14 funds opened new Matinas BioPharma positions in Q4 2018 and 10 closed out, a net change of +4 holders.
- The largest Matinas BioPharma buyer in Q4 2018 was Boxer Capital, an estimated $4.43M added.
- The largest Matinas BioPharma seller in Q4 2018 was Goldman Sachs, an estimated $261K sold.
Based on aggregated 13F filings for Q4 2018.